Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Angiogenesis
Published in: Angiogenesis 3/2008

01-09-2008 | Original Paper

Lysophosphatidic acid (LPA) and angiogenesis

Authors: Carol M. Rivera-Lopez, Amy L. Tucker, Kevin R. Lynch

Published in: Angiogenesis | Issue 3/2008

Login to get access

Abstract

Lysophosphatidic acid (LPA) is a simple lipid with many important biological functions such as the regulation of cellular proliferation, cellular migration, differentiation, and suppression of apoptosis. Although a direct angiogenic effect of LPA has not been reported to date, there are indications that LPA promotes angiogenesis. In addition, LPA is a chemoattractant for cultured endothelial cells and promotes barrier function in such cultures [1]. To test the hypothesis that LPA is angiogenic, we used the chicken chorio-allantoic membrane (CAM) assay. Sequence analysis of the cloned, full-length chicken LPA receptor cDNAs revealed three receptor types that are orthologous to the mammalian LPA1, LPA2, and LPA3 receptors. We document herein that LPA is angiogenic in the CAM system and further that synthetic LPA receptor agonists and antagonists mimic or block this response, respectively. Our results predict that LPA receptor antagonists are a possible therapeutic route to interdicting angiogenesis
Literature
1.
English D, Kovala AT, Welch Z, Harvey KA, Siddiqui RA, Brindley DN, Garcia JG (1999) Induction of endothelial cell chemotaxis by sphingosine 1-phosphate and stabilization of endothelial monolayer barrier function by LPA, potential mediators of hematopoietic angiogenesis. J Hematother Stem Cell Res 8(6):627–634PubMedCrossRef
2.
Duriex ME, Lynch KR (1993) Signaling properties of lysophosphatidic acid. Trends Pharmacol Sci 14:249–254CrossRef
3.
Goodemote KA, Mattie ME, Berger A, Spiegel S (1995) Involvement of a pertussis toxin-sensitive G protein in the mitogenic signaling pathways of sphingosine–1-phosphate. J Biol Chem 270:10272–10277PubMedCrossRef
4.
Ridley AJ, Hall A (1992) The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70:389–399PubMedCrossRef
5.
Postma FR, Jalink K, Hengeveld T, Moolenar WH (1996) Sphingosine-1-phosphate rapidly induces rho-dependent neurite retraction: action through a specific cell surface receptor. EMBO J 15:2388–2395PubMed
6.
Noguchi K, Ishii S, Shimizu T (2003) Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem 278:25600–25606PubMedCrossRef
7.
Lee CW, Rivera R, Gardell S, Dubin AE, Chun J (2006) GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J Biol Chem 281:23589–23597PubMedCrossRef
8.
Van Koppen CJ, Heringdorf DMZ, Laser KT, Zhang CY, Jakobs KH, Bunemann M, Pott L (1996) Activation of a high affinity Gi protein-coupled plasma membrane receptor by sphingosine 1-phosphate. J Biol Chem 271:2082–2087PubMedCrossRef
9.
Fromm C, Coso OA, Montaner S, Xu N, Gutkind JS (1997) The small GTP-binding protein Rho links G protein-coupled receptors and Galpha 12 to the serum response element and to cellular transformation. Proc Natl Acad Sci USA 94:10098–10103PubMedCrossRef
10.
Ghosh S, Strum JC, Bell RM (1997) Lipid biochemistry: functions of glycerolipids and sphingolipids in cellular signaling. FASEB J 11:45–50PubMed
11.
Bian D, Su S, Mahanivong C, Cheng RK, Han Q, Pan ZK, Sun P, Huang S (2004) Lysophosphatidic acid stimulates ovarian cancer cell migration via a Ras-MEK kinase 1 pathway. Cancer Res 64:4209–4217PubMedCrossRef
12.
Contos JJ, Ishii I, Fukushima N, Kingsbury MA, Ye X, Kawamura S, Brown JH, Chun J (2002) Characterization of lpa2 (Edg4) and lpa1/lpa2 (Edg4/Edg2) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa2. Mol Cell Biol 22:6921–6929PubMedCrossRef
13.
Ye X, Hama K, Contos JJ, Anliker B, Inoue A, Skinner MK, Suzuki H, Amano T, Kennedy G, Arai H, Aoki J, Chun J (2005) LPA3-mediated lysophosphatidic acid signaling in embryo implantation and spacing. Nature 435:104–108PubMedCrossRef
14.
Baker DL, Desiderio DM, Miller DD, Tolley B, Tigyi GJ (2001) Direct quantitative analysis of lysophosphatidic acid molecular species by stable isotope dilution electrospray ionization liquid chromatography-mass spectrometry. Anal Biochem 292:287–295PubMedCrossRef
15.
Saulnier-Blache JS, Girard A, Simon MF, Lafontan M, Valet P (2000) A simple and highly sensitive radioenzymatic assay for lysophosphatidic acid quantification. J Lipid Res 41:1947–1951PubMed
16.
Pages C, Simon MF, Valet P, Saulnier-Blache JS (2001) Lysophosphatidic acid synthesis and release. Prostaglandins Other Lipid Mediat 64:1–10PubMedCrossRef
17.
Saba JD (2004) Lysophospholipids in development: miles apart and edging in. J Cell Biochem 92:967–992PubMedCrossRef
18.
Lee H, Goetzl EJ, An S (2000) Lysophosphatidic acid and sphingosine 1-phosphate stimulate endothelial cell wound healing. Am J Physiol Cell Physiol 278:C612–C618PubMed
19.
English D, Kovala AT, Welch Z, Harvey KA, Siddiqui RA, Brindley DN, Garcia JG (1999) Induction of endothelial cell chemotaxis by sphingosine 1-phosphate and stabilization of endothelial monolayer barrier function by lysophosphatidic acid, potential mediators of hematopoietic angiogenesis. J Hematother Stem Cell Res 8(6):627–634PubMedCrossRef
20.
Wu WT, Chen CN, Lin CI, Chen JH, Lee H (2005) Lysophospholipids enhance matrix metalloproteinase-2 expression in human endothelial cells. Endocrinology 146:3387–3400PubMedCrossRef
21.
Nam SW, Clair T, Kim YS, McMarlin A, Schiffmann E, Liotta LA, Stracke ML (2001) Autotaxin (NPP–2), a metastasis-enhancing mitogen, is an angiogenic factor. Cancer Res 61:6938–6944PubMed
22.
van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, Pradere JP, Pettit TR, Wakelam MJO, Saulnier-Blache JS, Mummery CL, Moolenaar WH, Jonkers J (2006) Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol 26(13):5015–5022PubMedCrossRef
23.
Sabbadini RA (2006) Targeting sphingosine-1-phosphate for cancer therapy. Br J Cancer 95:1131–1135PubMedCrossRef
24.
Heasley BH, Jarosz R, Lynch KR, Macdonald TL (2004) Initial structure-activity relationships of lysophosphatidic acid receptor antagonist: discovery of a high-affinity LPA1/LPA3 receptor antagonist. Bioorg Med Chem Lett 14:2735–2740PubMedCrossRef
25.
Hasegawa Y, Erickson JR, Goddard GJ, Yu S, Liu S, Cheng KW, Eder A, Bandoh K, Aoki J, Jarosz R, Schrier AD, Lynch KR, Mills GB, Fang X (2003) Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor. J Biol Chem 278:11962–11969PubMedCrossRef
26.
Lee S, Lynch KR (2005) Brown recluse spider (Loxosceles reclusa) venom phospholipase D (PLD) generates lysophosphatidic acid (LPA). Biochem J 391:317–323PubMedCrossRef
27.
van Meeteren LA, Frederiks F, Giepmans BN, Pedrosa MF, Billington SJ, Jost BH, Tambourgi DV, Moolenaar WH (2004) Spider and bacterial sphingomyelinases D target cellular lysophosphatidic acid receptors by hydrolyzing lysophosphatidylcholine. J Biol Chem 279(12):10833–10836PubMedCrossRef
28.
Goetzl EJ, An S (1998) Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. FASEB J 12:1589–1598PubMed
29.
Koutrafouri V, Leondiadis L, Avgoustakis K, Livaniou E, Czarnecki J, Ithakissios DS, Evangelatos GP (2001) Effect of thymosin peptides on the chick chorioallantoic membrane angiogenesis model. Biochim Biophys Acta 1568:60–66PubMed
30.
Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6:273–286PubMedCrossRef
31.
Chen CH, Walterscheid JP (2006) Plaque angiogenesis versus compensatory arteriogenesis in atherosclerosis. Circ Res 99:787–789PubMedCrossRef
32.
Metadata
Title
Lysophosphatidic acid (LPA) and angiogenesis
Authors
Carol M. Rivera-Lopez
Amy L. Tucker
Kevin R. Lynch
Publication date
01-09-2008
Publisher
Springer Netherlands
Published in
Angiogenesis / Issue 3/2008
Print ISSN: 0969-6970
Electronic ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-008-9113-5

Other articles of this Issue 3/2008

Angiogenesis 3/2008 Go to the issue

Review Paper

The discovery of the placental growth factor and its role in angiogenesis: a historical review

Original Paper

Anti-angiogenic activity of sesterterpenes; natural product inhibitors of FGF-2-induced angiogenesis

Original Paper

Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anti-cancer agent

Original Paper

VEGF165 expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing’s sarcoma vasculature

Original Paper

Fibroblasts potentiate blood vessel formation partially through secreted factor TIMP-1

Original Paper

Video monitoring of neovessel occlusion induced by photodynamic therapy with verteporfin (Visudyne®), in the CAM model
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits